ExecuPharm, Inc.

Private | Salec | PAREXEL International Corporation

Leading global functional service provider serving pharmaceutical companies with qualified professionals across functional areas, such as clinical monitoring and study management

Case

Delancey Street Partners is pleased to announce that we served as financial advisor to ExecuPharm, Inc. (“ExecuPharm” or “the Company”), a leading global functional service provider, in its sale to PAREXEL International Corporation (“PAREXEL”).

October 2016
ExecuPharm, Inc.
Sale to PAREXEL International Corporation (NASDAQ: PRXL)
Sector: Healthcare Services
Delancey Street Partners served as the exclusive financial advisor to ExecuPharm, Inc.

Delancey Street Partners is pleased to announce that we served as financial advisor to ExecuPharm, Inc. (“ExecuPharm” or “the Company”), a leading global functional service provider, in its sale to PAREXEL International Corporation (“PAREXEL”).

About

October 2016
ExecuPharm, Inc.
Sale to PAREXEL International Corporation (NASDAQ: PRXL)
Sector: Healthcare Services
Delancey Street Partners served as the exclusive financial advisor to ExecuPharm, Inc.

Situation

ExecuPharm selected Delancey as its advisor for our M&A expertise and long-term partnership model. Over several years we partnered with the Company to assess, evaluate and explore strategic alternatives within the context of the rapidly evolving and dynamic pharmaceutical industry. We managed a highly selective and targeted sell-side M&A process and structured and negotiated the terms of the transaction.

Established in 1995, ExecuPharm (www.execupharm.com) provides clients with qualified professionals across functional areas, such as clinical monitoring and study management. The Company also provides core operational activities including onboarding, training, line management, performance management and policy administration. The Company is headquartered in King of Prussia, Pennsylvania, and serves many of the top 20 pharmaceutical corporations, as well as mid-sized and small biopharmaceutical companies.

PAREXEL (www.PAREXEL.com) is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and has approximately 18,600 employees.

Result

The transaction was completed October 3, 2016.

The principals of Delancey Street Partners have significant experience serving the Healthcare industry.

For additional information about this transaction, please contact:

Additional

Information

The transaction was completed October 3, 2016.

The principals of Delancey Street Partners have significant experience serving the Healthcare industry.

For additional information about this transaction, please contact:

B. Andrew Schmucker

Managing Partner Phone: (484) 533 – 6313

B. Andrew Schmucker

Click to Email

We Work With
Great Companies

We want to work with you. Contact us to learn how we can assist in maximizing the value of your business.